PriceTargets.com logo

NYSEAMERICAN:MYO - Myomo Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.33
  • Forecasted Upside: 8.57 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.36 As of 06/16/2021 01:00 AM ET
▼ -0.39 (-3.32%)
1 month | 3 months | 12 months
Get New Myomo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.33
▲ +8.57% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Myomo in the last 3 months. The average price target is $12.33, with a high forecast of $16.00 and a low forecast of $7.00. The average price target represents a 8.57% upside from the last price of $11.36.

Buy

The current consensus among 3 contributing investment analysts is to buy stock in Myomo. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/10/2021Alliance Global PartnersInitiated CoverageBuy
i
3/8/2021Colliers SecuritiesReiterated RatingBuy$16.00
i
1/11/2021SidotiBoost Price Target$11.00 ➝ $14.00
i
11/11/2020Roth CapitalUpgradeNeutral ➝ Buy$7.00
i
Rating by S. Henry at Roth Capital
9/16/2020Colliers SecuritiesBoost Price TargetBuy$7.00 ➝ $8.00
i
5/27/2020Dougherty & CoReiterated RatingBuy
i
Rating by K. Bauser at Dougherty & Co
5/27/2020Dougherty & CoInitiated CoverageBuy$8.50
i
Rating by K. Bauser at Dougherty & Co
3/23/2020Ascendiant Capital MarketsLower Price TargetPositive ➝ Buy$45.00 ➝ $15.00
i
11/14/2019Roth CapitalDowngradeBuy ➝ Neutral
i
11/13/2019Roth CapitalDowngradeBuy ➝ Neutral
i
Rating by S. Henry at Roth Capital
8/30/2019Roth CapitalSet Price TargetBuy$2.00
i
Rating by Scott Henry at Roth Capital
8/30/2019Roth CapitalLower Price TargetBuy$2.75 ➝ $1.75
i
7/30/2019Ascendiant Capital MarketsInitiated CoverageBuy$2.00
i
2/5/2019Roth CapitalReiterated RatingBuy
i
Rating by S. Henry at Roth Capital
11/8/2018Roth CapitalReiterated RatingBuy
i
Rating by D. Solomon at Roth Capital
8/14/2018HC WainwrightSet Price TargetBuy$12.00
i
Rating by Amit Dayal at HC Wainwright
5/10/2018Roth CapitalSet Price TargetBuy$9.00 ➝ $7.00
i
Rating by Scott Henry at Roth Capital
5/10/2018HC WainwrightSet Price TargetBuy$12.00
i
Rating by Amit Dayal at HC Wainwright
3/9/2018Roth CapitalInitiated CoverageBuy$9.00
i
3/8/2018HC WainwrightSet Price TargetBuy$12.00
i
Rating by Amit Dayal at HC Wainwright
10/2/2017HC WainwrightReiterated RatingBuy
i
Rating by A. Dayal at HC Wainwright
10/2/2017HC WainwrightInitiated CoverageBuy ➝ Buy$12.00
i
(Data available from 6/16/2016 forward)
Myomo logo
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $11.36
$11.31
$11.80

50 Day Range

MA: $6.89
$6.47
$7.53

52 Week Range

Now: $11.36
$3.46
$18.88

Volume

43,248 shs

Average Volume

149,571 shs

Market Capitalization

$63.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Myomo?

The following Wall Street sell-side analysts have issued research reports on Myomo in the last twelve months: Alliance Global Partners, Colliers Securities, Roth Capital, Sidoti, and Zacks Investment Research.
View the latest analyst ratings for MYO.

What is the current price target for Myomo?

3 Wall Street analysts have set twelve-month price targets for Myomo in the last year. Their average twelve-month price target is $12.33, suggesting a possible upside of 5.9%. Colliers Securities has the highest price target set, predicting MYO will reach $16.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $7.00 for Myomo in the next year.
View the latest price targets for MYO.

What is the current consensus analyst rating for Myomo?

Myomo currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MYO will outperform the market and that investors should add to their positions of Myomo.
View the latest ratings for MYO.

What other companies compete with Myomo?

Other companies that are similar to Myomo include Sanara MedTech, Conformis, Lakeland Industries, Surgalign, Milestone Scientific, CollPlant Biotechnologies, Alpha Pro Tech, Nutriband, ReWalk Robotics, Predictive Oncology, NanoVibronix, Allied Healthcare Products, Advanced Biomedical Technologies, Bionik Laboratories and Avitar.

How do I contact Myomo's investor relations team?

Myomo's physical mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company's listed phone number is +1-617-9969058 and its investor relations email address is [email protected] The official website for Myomo is myomo.com.